2024年7月12日 · Tardive dyskinesia (TD) is a movement disorder characterized by hyperkinetic, complex choreiform movements associated with the use of antipsychotic medications. TD …

2017年6月6日 · Phase 3 trials showed improved movement and quality-of-life scores for deutetrabenazine-treated patients with tardive dyskinesia, leading the FDA to grant priority …

2015年10月9日 · NBI-98854, an experimental drug for tardive dyskinesia being developed by Neurocrine Biosciences, led to a statistically significant reduction in symptoms of the …

2017年8月30日 · Tardive dyskinesia (TD) is a debilitating and often irreversible movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, …

Incidence rates of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A priori hypothesized associations between incident TDD and other dopamine …

2024年7月29日 · Tardive dyskinesia, often underdiagnosed and undertreated, hinders patient adherence to antipsychotics, affecting mental health treatment and caregivers' well-being, …

Incidence of Tardive Dystonia, Tardive Dyskinesia and TDD for Each Time Band (n = 3104) Tardive dystonia TD TDD; N ... a As some patients may present with both tardive dystonia and …

2016年6月30日 · In the phase 3 KINECT 3 trial, investigational drug valbenazine reduced tardive dyskinesia among psychiatric patients receiving antipsychotic medications, with a favorable …

2022年4月19日 · A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients …

Incidence of Tardive Dystonia, Tardive Dyskinesia and TDD for Each Time Band (n = 3104) Tardive dystonia TD TDD; N ... a As some patients may present with both tardive dystonia and …